Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific
Poster #795 entitled, "APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIR™ technology designed to deliver a conditional T cell/NK response against solid tumors," will be presented and displayed on-site on
"APVO603 is a differentiated bispecific antibody with the potential to leverage the benefits of 4-1BB and OX40 in a single agent. Further, the tethering of molecules has the potential to reduce safety risks and improve potency profiles by targeting responses specifically to sites of active inflammation and limiting on-target toxicity," said
Aptevo CEO
Title: APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIRTM technology designed to deliver a conditional T cell/NK response against solid tumors
Presenter:
Date/Time:
About APVO603
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF Receptor Superfamily. Dual targeting of 4-1BB and OX40 provides synergistic co-stimulation of T cells with the potential to amplify the cytotoxic function of activated T cells and NK cells, potentially leading to more robust anti-tumor responses.
About
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy and safety of its therapeutic candidates and potential use of any such candidates as therapeutics for treatment of disease, advancement of its clinical trials and its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "optimism," "potential," "designed," "engineered," "breakthrough," "innovative," "innovation," "promising," "plans," "forecasts," "estimates," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; adverse developments in the
CONTACTS:
Investors
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6629
Media
Email: jabraham@jqapartners.com
Phone: 917-884-7378
SOURCE:
accesswire.com
https://www.accesswire.com/672334/Aptevo-Therapeutics-Announces-Preclinical-Data-for-Bispecific-Antibody-APVO603-at-the-Society-for-Immunology-in-Cancer-Annual-Meeting